Richard Pazdur (vis AACR)
Roche, Bristol Myers, and Merck prep defense for 6 ‘dangling’ PD-(L)1 accelerated approvals, even though they failed confirmatory trials
Should 6 significant accelerated approvals for 3 of the top PD-(L)1s on the market get yanked or stand unchanged, even though they failed key required …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.